Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

W. Timothy Garvey, Anuj Bhargava, José Francisco Kerr Saraiva et al.|The Lancet|2023

Cited by 676